Drug Profile


Alternative Names: Atorvastatin/ramipril/S-metoprolol; Metpure AR; Ramipril/atorvastatin/S-metoprolol; Ramipril/S-metoprolol/atorvastatin; S-metoprolol/atorvastatin/ramipril; S-metoprolol/ramipril/atorvastatin

Latest Information Update: 09 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Emcure Pharmaceuticals
  • Class Antihyperlipidaemics; Antihypertensives; Antimigraines; Class II antiarrhythmics; Fatty acids; Heart failure therapies; Heptanoic acids; Heterocyclic bicyclo compounds; Propanolamines; Pyrroles; Small molecules
  • Mechanism of Action ACE inhibitors; Beta 1 adrenergic receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension; Hypercholesterolaemia

Most Recent Events

  • 09 Oct 2015 No recent reports on development identified - Phase-III for Essential hypertension (Treatment-naive) in India (PO)
  • 10 Aug 2015 Launched for Essential hypertension in India (PO) before August 2015
  • 10 Aug 2015 Launched for Hypercholesterolaemia in India (PO) before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top